Study Population
Adults (≥18 years) within the UNOS data registry who received a
first-time OHT between 2010 and 2018 were included. Exclusion criteria
included recipients of multi-visceral transplants, those undergoing redo
OHT, centers with less than 45 cumulative transplants during the study
period and recipients with more than 20% missing recipient data. The
types of induction therapy evaluated in the study were interleukin 2
(IL-2) receptor antagonists (basiliximab and daclizumab) as well as
polyclonal and monoclonal anti-thymocyte antibodies (thymoglobulin,
atgam, muromonab OKT3 and alemtuzumab).